THE CURAPEL APPROACH
The Curapel team understands that people want to use products that contains safe, naturally-occurring ingredients that are backed up by science and dermatological testing. To date, Curapel has expanded its IP portfolio to 30 granted and 4 pending, patent applications, allowing us to continue product development across several sectors; eczema, psoriasis, skin pigmentation, skin microbiome, gut-skin axis and transdermal delivery. All products are developed using safe, naturally-occurring ingredients and are dermatologically validated before launch.
In summary, Curapel epitomises the successful translation of academic research to commercial products that safely meet the unmet clinical needs of people with chronic skin conditions. We continue to take our exciting product pipeline into the market to reap potentially substantial returns for our investors, stakeholders and strategic partners.
TERRY SADLER, CHAIRMAN
Terry has over 40 years of experience in the Healthcare Industry at all levels with positions including CEO and Public Company Chairman. As the former Chairman & CEO of Bioglan Pharma Plc, Terry built a UK FTSE 250 Company over a 17 year period and won the UK Master Entrepreneur award in 2000. In 2014, Terry negotiated with the University of Manchester the terms and structure of the spin-out of Curapel from the University. Since then, he has acted as Chairman of Curapel and mentored the directorate, assisted and participated in fundraising, managing and concluding the company’s first commercial licensing agreement in 2019 with a multinational company.
DR PETER LUEBCKE, CEO
Following a degree in chemistry and a PhD in physics from Cambridge University, Peter has accumulated over 25 years’ experience in innovation management across various sectors such as university tech-transfer, start-up companies and in the tier 1 product development companies Cambridge Consultants and Sagentia. Peter became CEO of Curapel in 2016 and since then has raised over £1 million in investment and grants for Curapel. He has also been instrumental in bringing the company’s first product to market in conjunction with implementing a global multi-million pound licensing deal. Peter is continually building on a strong track record of business development in the personal and consumer healthcare industries by identifying distinct market opportunities that can be fulfilled by patentable products.
DR NEIL GIBBS, FOUNDER & CSO
BSc, MPhil, PhD, FRSB
Neil is a skin biologist who has worked in the Dermatology sector for the last 40 years. He initially undertook post-graduate research at St John’s Institute for Dermatology, London where he was awarded an MPhil and PhD. He then took Lectureships in the Dermatology departments of Dundee and Manchester Universities. Neil has published over 70 peer-reviewed papers on skin biology and is a past Co-Editor of Clinical & Experimental Dermatology and Associate Editor of The Journal of Investigative Dermatology. Neil is a Royal Society of Edinburgh Enterprise Fellow and winner of the BBSRC ‘Commercial Innovator of the Year’ in 2018. He founded Curapel and spun the company out of the University of Manchester in 2014.
ALAN WILLIAMS, FINANCIAL DIRECTOR
Alan acts for Curapel in a finance director capacity, to support the board in strategic and financial matters. Alan is commercially driven and practical, with strong project management skills and a track record of delivering successful outcomes. Alan’s key skill sets include financial modelling, business planning, development of financial management functions, and corporate transactions.
Alan has over 25 years experience as a chartered accountant, having qualified with PwC before working for a further 19 years as a senior manager within PwC’s Advisory services. Subsequently Alan has worked independently as a portfolio finance director, specialising in the community pharmacy sector where he has undertaken several finance director roles over the last 5 years.
The Curapel team at the launch of Pellamex, The Royal Society of Medicine, London, 2017